Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ANIK's Cash to Debt is ranked higher than
84% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. ANIK: No Debt )
ANIK' s 10-Year Cash to Debt Range
Min: 1.5   Max: No Debt
Current: No Debt

Equity to Asset 0.92
ANIK's Equity to Asset is ranked higher than
95% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ANIK: 0.92 )
ANIK' s 10-Year Equity to Asset Range
Min: 0.49   Max: 0.94
Current: 0.92

0.49
0.94
Interest Coverage No Debt
ANIK's Interest Coverage is ranked higher than
65% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ANIK: No Debt )
ANIK' s 10-Year Interest Coverage Range
Min: 38.66   Max: 9999.99
Current: No Debt

38.66
9999.99
F-Score: 7
Z-Score: 24.30
M-Score: -2.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 57.72
ANIK's Operating margin (%) is ranked higher than
98% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. ANIK: 57.72 )
ANIK' s 10-Year Operating margin (%) Range
Min: -65.51   Max: 43.43
Current: 57.72

-65.51
43.43
Net-margin (%) 35.87
ANIK's Net-margin (%) is ranked higher than
96% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. ANIK: 35.87 )
ANIK' s 10-Year Net-margin (%) Range
Min: -60.87   Max: 42.28
Current: 35.87

-60.87
42.28
ROE (%) 24.69
ANIK's ROE (%) is ranked higher than
97% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. ANIK: 24.69 )
ANIK' s 10-Year ROE (%) Range
Min: -44.09   Max: 46.29
Current: 24.69

-44.09
46.29
ROA (%) 21.82
ANIK's ROA (%) is ranked higher than
97% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. ANIK: 21.82 )
ANIK' s 10-Year ROA (%) Range
Min: -33.73   Max: 27.49
Current: 21.82

-33.73
27.49
ROC (Joel Greenblatt) (%) 103.51
ANIK's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. ANIK: 103.51 )
ANIK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -171.43   Max: 222.6
Current: 103.51

-171.43
222.6
Revenue Growth (%) 7.50
ANIK's Revenue Growth (%) is ranked higher than
84% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. ANIK: 7.50 )
ANIK' s 10-Year Revenue Growth (%) Range
Min: -4.5   Max: 26.7
Current: 7.5

-4.5
26.7
EBITDA Growth (%) 46.60
ANIK's EBITDA Growth (%) is ranked higher than
97% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. ANIK: 46.60 )
ANIK' s 10-Year EBITDA Growth (%) Range
Min: -65.1   Max: 95.7
Current: 46.6

-65.1
95.7
EPS Growth (%) 63.20
ANIK's EPS Growth (%) is ranked higher than
98% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. ANIK: 63.20 )
ANIK' s 10-Year EPS Growth (%) Range
Min: -64.3   Max: 72.4
Current: 63.2

-64.3
72.4
» ANIK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ANIK Guru Trades in Q4 2013

Joel Greenblatt Sold Out
Jim Simons 396,800 sh (-1.32%)
Chuck Royce 1,600 sh (-15.79%)
» More
Q1 2014

ANIK Guru Trades in Q1 2014

Paul Tudor Jones 10,653 sh (New)
Jim Simons 442,400 sh (+11.49%)
Chuck Royce 1,300 sh (-18.75%)
» More
Q2 2014

ANIK Guru Trades in Q2 2014

Joel Greenblatt 235,399 sh (New)
Chuck Royce 1,300 sh (unchged)
Jim Simons 367,400 sh (-16.95%)
Paul Tudor Jones 6,759 sh (-36.55%)
» More
Q3 2014

ANIK Guru Trades in Q3 2014

Joel Greenblatt 375,753 sh (+59.62%)
Chuck Royce Sold Out
Paul Tudor Jones Sold Out
Jim Simons 270,600 sh (-26.35%)
» More
» Details

Insider Trades

Latest Guru Trades with ANIK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Add 59.62%0.05%$36.48 - $50.43 $ 38.38-11%375753
Joel Greenblatt 2014-06-30 New Buy0.14%$37.71 - $48.86 $ 38.38-14%235399
Joel Greenblatt 2013-12-31 Sold Out 0.05%$23.64 - $38.09 $ 38.3824%0
Joel Greenblatt 2013-09-30 New Buy0.05%$17.74 - $27.28 $ 38.3870%68532
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 16.00
ANIK's P/E(ttm) is ranked higher than
98% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ANIK: 16.00 )
ANIK' s 10-Year P/E(ttm) Range
Min: 8.66   Max: 158.59
Current: 16

8.66
158.59
P/B 3.35
ANIK's P/B is ranked higher than
82% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. ANIK: 3.35 )
ANIK' s 10-Year P/B Range
Min: 0.58   Max: 6.39
Current: 3.35

0.58
6.39
P/S 5.71
ANIK's P/S is ranked higher than
88% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. ANIK: 5.71 )
ANIK' s 10-Year P/S Range
Min: 1   Max: 9.2
Current: 5.71

1
9.2
PFCF 18.54
ANIK's PFCF is ranked higher than
97% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ANIK: 18.54 )
ANIK' s 10-Year PFCF Range
Min: 3.71   Max: 1445
Current: 18.54

3.71
1445
EV-to-EBIT 7.78
ANIK's EV-to-EBIT is ranked higher than
98% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ANIK: 7.78 )
ANIK' s 10-Year EV-to-EBIT Range
Min: 1.8   Max: 190.1
Current: 7.78

1.8
190.1
PEG 0.37
ANIK's PEG is ranked higher than
100% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ANIK: 0.37 )
ANIK' s 10-Year PEG Range
Min: 0.29   Max: 10.15
Current: 0.37

0.29
10.15
Shiller P/E 40.93
ANIK's Shiller P/E is ranked higher than
97% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ANIK: 40.93 )
ANIK' s 10-Year Shiller P/E Range
Min: 6.22   Max: 178.13
Current: 40.93

6.22
178.13
Current Ratio 20.00
ANIK's Current Ratio is ranked higher than
95% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. ANIK: 20.00 )
ANIK' s 10-Year Current Ratio Range
Min: 2.84   Max: 20
Current: 20

2.84
20
Quick Ratio 17.89
ANIK's Quick Ratio is ranked higher than
94% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. ANIK: 17.89 )
ANIK' s 10-Year Quick Ratio Range
Min: 1.21   Max: 17.89
Current: 17.89

1.21
17.89

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.48
ANIK's Price/Net Cash is ranked higher than
85% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. ANIK: 7.48 )
ANIK' s 10-Year Price/Net Cash Range
Min: 0.16   Max: 79.94
Current: 7.48

0.16
79.94
Price/Net Current Asset Value 5.80
ANIK's Price/Net Current Asset Value is ranked higher than
87% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. ANIK: 5.80 )
ANIK' s 10-Year Price/Net Current Asset Value Range
Min: 0.14   Max: 537.5
Current: 5.8

0.14
537.5
Price/Tangible Book 3.92
ANIK's Price/Tangible Book is ranked higher than
85% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. ANIK: 3.92 )
ANIK' s 10-Year Price/Tangible Book Range
Min: 0.12   Max: 16.28
Current: 3.92

0.12
16.28
Price/DCF (Projected) 1.90
ANIK's Price/DCF (Projected) is ranked higher than
97% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ANIK: 1.90 )
ANIK' s 10-Year Price/DCF (Projected) Range
Min: 0.48   Max: 20.72
Current: 1.9

0.48
20.72
Price/Median PS Value 1.47
ANIK's Price/Median PS Value is ranked higher than
79% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. ANIK: 1.47 )
ANIK' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 2.42
Current: 1.47

0.12
2.42
Price/Peter Lynch Fair Value 0.64
ANIK's Price/Peter Lynch Fair Value is ranked higher than
100% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ANIK: 0.64 )
ANIK' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.37   Max: 5.53
Current: 0.64

0.37
5.53
Price/Graham Number 1.63
ANIK's Price/Graham Number is ranked higher than
97% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ANIK: 1.63 )
ANIK' s 10-Year Price/Graham Number Range
Min: 0.08   Max: 9.67
Current: 1.63

0.08
9.67
Earnings Yield (Greenblatt) 12.90
ANIK's Earnings Yield (Greenblatt) is ranked higher than
98% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. ANIK: 12.90 )
ANIK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 56.4
Current: 12.9

0.5
56.4
Forward Rate of Return (Yacktman) 54.34
ANIK's Forward Rate of Return (Yacktman) is ranked higher than
97% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 15.36 vs. ANIK: 54.34 )
ANIK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -11.2   Max: 54.5
Current: 54.34

-11.2
54.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AKP.Germany,
Anika Therapeutics, Inc., was incorporated in 1992 as a Massachusetts company. The Company develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid, or HA, a naturally occurring, biocompatible polymer found throughout the body. Due to its biophysical and biochemical properties, HA performs physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues, and the transport of molecules to and within cells. The Company through tis subsidiary has over 20 products currently commercialized, mainly in Europe. These products are made from hyaluronic acid, based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Both technologies are protected by a portfolio of owned and licensed patents. The Company offers therapeutic products in various areas which include: Orthobiologics, Dermal, Surgical, Ophthalmic and Veterinary. Its Orthobiologics products consist of joint health and orthopedic products. These products are used in a range of treatments from providing relief from the pain of osteoarthritis, to regenerating damaged tissue such as cartilage defects. Its joint health products include ORTHOVISC, ORTHOVISC mini, and MONOVISC. ORTHOVISC is available in the U.S., Canada, Turkey and other international markets for the treatment of osteoarthritis of the knee, and in Europe for the treatment of osteoarthritis in all joints. Its Dermal products consist of advanced wound care products, based on the HYAFF technology, and aesthetic dermal fillers. The HYAFF technology offers products for the treatment of skin wounds, ranging from burns to diabetic ulcers. The products cover a variety of wound treatment solutions including debridement agents, advanced therapies to aid healing and skin substitutes. Its ophthalmic business includes HA viscoelastic products used in ophthalmic surgery. These products include AMVISC and AMVISC Plus product line, STAARVISC-IITM, Optivisc, AnikaVisc and AnikaVisc Plus which are injectable, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures such as cataract extraction and intraocular lens implantation. Its surgical business consists of products used to prevent surgical adhesions, and to treat ENT disorders. Hyalobarrier is a clinically proven post-operative adhesion barrier for use in the abdomino-pelvic area. The product is currently commercialized in Europe, the Middle East and certain Asian countries through a distribution network, but is not approved in the U.S. INCERT, approved for sale in Europe, Turkey, and Malaysia. It is chemically modified, cross-linked HA product for the prevention of spinal post-surgical adhesions. The Company along with its subsidiary offers products used in connection with the treatment of ENT disorders. The products are M
» More Articles for ANIK

Headlines

Articles On GuruFocus.com
WEEKLY CFO SELLS HIGHLIGHT: ANIK, GILD, PETM, NKE, ADBE Mar 31 2013 
comment on ANIK Apr 29 2012 
Not bad for a small Aug 06 2011 
Anika Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Anika Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Anika Therapeutics Inc. Reports Operating Results (10-Q) Nov 03 2009 
Anika Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2009 
Anika Therapeutics Inc. Reports Operating Results (10-Q) May 05 2009 

More From Other Websites
ANIKA THERAPEUTICS, INC. Financials Nov 14 2014
Center for Medicare & Medicaid Services Announces That a Unique Reimbursement Code is Assigned to... Nov 10 2014
Center for Medicare & Medicaid Services Announces That a Unique Reimbursement Code is Assigned to... Nov 10 2014
10-Q for Anika Therapeutics, Inc. Nov 09 2014
ANIKA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Nov 06 2014
ANIKA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Nov 03 2014
Anika Therapeutics Inc Earnings Call scheduled for 9:00 am ET today Oct 30 2014
Anika Therapeutics Reports Third-Quarter 2014 Financial Results Oct 29 2014
ANIKA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Oct 29 2014
Anika Therapeutics Reports Third-Quarter 2014 Financial Results Oct 29 2014
Q3 2014 Anika Therapeutics Inc Earnings Release - After Market Close Oct 29 2014
Anika Therapeutics Announces Date of Third-Quarter 2014 Financial Results Conference Call Oct 16 2014
Anika Therapeutics Announces Date of Third-Quarter 2014 Financial Results Conference Call Oct 16 2014
Lessons To Take From Health Care's Strong 2014 And What To Buy Now Aug 25 2014
ANIKA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Aug 04 2014
Anika Therapeutics to Present at Canaccord Genuity 34th Annual Growth Conference Aug 04 2014
Major Indexes Extend Losses; S&P 500 Breaks 50-Day Line Jul 31 2014
ANIKA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 30 2014
Anika Therapeutics Reports Second-Quarter 2014 Financial Results Jul 30 2014
Anika Therapeutics Announces U.S. Commercialization Partnership for Hyalomatrix® with Wound Care... Jul 30 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK